EU/3/20/2290: Orphan designation for the treatment of primary hyperoxaluria



On 26 June 2020, orphan designation EU/3/20/2290 number was granted by the European Commission to Biocodex S.A.S., France, for stiripentol for the treatment of primary hyperoxaluria.

Key facts

Active substance
Intended use
Treatment of primary hyperoxaluria
Orphan designation status
EU designation number
Date of designation

Biocodex S.A.S.
7 Avenue Gallieni
94250 Gentilly
Tel. + 33 1412 43000

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating